期刊
CANCER INVESTIGATION
卷 40, 期 7, 页码 590-603出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/07357907.2022.2069254
关键词
Osimertinib; almonertinib; furmonertinib
类别
This article reviews the research advances of three third-generation EGFR-TKIs, namely osimertinib, almonertinib, and furmonertinib, in terms of pharmacokinetics, pharmacodynamics, treatment-related adverse events, and other aspects. Individualized optimization of third-generation EGFR-TKIs options may provide maximum benefits to NSCLC patients with EGFR T790M mutation.
Osimertinib, almonertinib and furmonertinib are third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) approved for non-small cell lung cancer (NSCLC) patients with EGFR T790M mutation. This article reviews research advances in pharmacokinetics, pharmacodynamics, treatment-related adverse events, and other aspects related to the three EGFR-TKIs were systematically reviewed in order to provide references for clinical drug selection. There are differences in dosing schedule and incidence of adverse events among three drugs. Optimization of third-generation EGFR-TKIs options for individuals may produce the maximal benefits to NSCLC patients with EGFR T790M mutation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据